大跌。补体新药欧洲坏消息。
APLS announced an update on the ongoing review of its marketing authorization application (MAA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Apellis was informed of a negative trend vote on the MAA for pegcetacoplan.